Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303602 · ClinicalTrials.gov registry record · Phase 4
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 149
- Enrollment target
NCT00303602 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 149 participants.
The verdict
NCT00303602, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 149 participants
- Enrollment target
Study Summary
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.
Interventions
- DRUG Sublingual orally disintegrating olanzapine (SODO)
- DRUG Oral olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303602
The ClinicalTrials.gov registry entry for NCT00303602 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sublingual orally disintegrating olanzapine (SODO) is the first listed.
NCT00303602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303602 about?
NCT00303602 is a clinical study titled "Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)". This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.
What is the current status of trial NCT00303602?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00303602?
The interventions under investigation include: Sublingual orally disintegrating olanzapine (SODO) (DRUG), Oral olanzapine (DRUG).
Who is sponsoring clinical trial NCT00303602?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.